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OBJECTIVES: The Pediatric Economic Database Evalu-
ation (PEDE) Project features a database of 787 pediatric
economic evaluations published between 1980 to 1999.
Our research objective was to use the PEDE database to
examine trends in the application of health economic
methods to a pediatric population.
METHODS: Frequency distributions and cross-
tabulations were performed on the following variables:
period of publication, age group, ICD-9-CM category,
intervention, outcome and analytic technique.
RESULTS: The number of publications increased six-fold
between 1980–84 to 1995–99 from 61 to 440 citations
per 5-year period. Thirty-two percent of all studies were
published in journals for pediatrics or perinatal medicine
and 26% appeared in sub-specialty journals. Cost-
effectiveness analyses were most frequent, representing
74% of all studies. Throughout the period, the propor-
tion of cost-effectiveness analyses increased by 50%, and
decreased for cost-beneﬁt and cost-minimization analy-
ses. Although most studies were performed in children 
(1–12 years of age), this frequency decreased with time
while studies in infants became more prevalent. Most
publications were classiﬁed under the infective and para-
sitic ICD-9-CM category, comprising 24% of studies.
Health prevention studies became less frequent and health
treatment studies more predominant with time. Most
studies consisted of malaria control and vaccination
strategies for hepatitis B, Hemophilus inﬂuenzae type B,
measles, and varicella. The most common health outcome
measure was cases of abnormality, which accounted for
42% of outcomes.
CONCLUSIONS: The number of pediatric economic
evaluations is steadily increasing with most publications
representing health prevention interventions. The major-
ity of publications include cost-effectiveness analyses,
especially among children aged 1 to 12 years. Further
research is ongoing to determine how the quality of the
studies has changed over time.
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OBJECTIVE: Information on Managed Care Organiza-
tions’ (MCOs) performance in managing direct and 
indirect costs (absenteeism and presenteeism) allows
employers to make more informed purchasing decisions.
This paper examines challenges in evaluating MCOs’
management of indirect costs.
METHODS: The framework for evaluating MCOs com-
pares “observed” to “expected” performance in manag-
ing lost productive work time (LPT) for a speciﬁc health
condition. A credible and fair evaluation requires: i) a 
reference database deﬁning “expected” LPT for a health
condition; ii) LPT data on a random sample of the MCOs
membership who work for pay deﬁning “observed” per-
formance; iii) metrics comparing observed to expected
LPT for a speciﬁc health condition; and iv) a method 
to translate metrics into an understandable performance
score. Issues related to each component are discussed
below.
RESULTS: i) The reference must provide credible data on
expected LPT for a speciﬁc health condition that includes
missed workdays and lost productive time while at work.
Self-reported information using a validated interview in 
a representative sample of US workers is one method.
Recall period and essential data elements need to be con-
sidered. ii) Data collection should be in a representative
sample of MCO members, interviewed using the reference
population instrument. Cost/interview and prevalence of
speciﬁc health conditions will drive sample size needs. iii)
Two comparative metrics of interest include a) condition-
speciﬁc prevalence; and b) LPT/week among those with
the condition. We propose logistic regression to model
LPT (a non-normally distributed variable) and adjust 
for covariates. iv) Resulting metrics must be translated
into simple, easy-to-use, and universally understood 
terminology.
CONCLUSIONS: In operationalizing the MCO evalua-
tion process, we consider a hypothetical application using
data from the American Productivity Audit (an on-going
national survey of health-related LPT) as a reference. We
will examine the 10 health conditions with the greatest
impact on work loss.
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In this study, two available methods of item reduction
(factor analysis and clinical impact) are compared to
determine the effect of the method of item reduction on
the ﬁnal PTRQoL instrument.
OBJECTIVE: To perform a factor analysis of 57-items of
the developmental-version of the PTRQoL (d-PTRQoL)
and to determine if the results differ from a previous 
clinical impact method item reduction of the same 
57-items.
METHODS: Factor analysis (using principal axis factor-
ing and direct oblimin method of rotation with 125 iter-
ations) was performed on a dataset accumulated from a
previous work to compare results of the clinical impact
item reduction from a separate dataset. The dataset (n =
182) used was obtained earlier by a survey of patients
from various community pharmacies using the d-
PTRQoL (93-items on a six-point likert scale). Factor
analysis was restricted to the same 57 items used in the
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earlier clinical impact item reduction, where Juniper 
et al’s clinical impact method was adapted on a dataset
with a ﬁve-point anchor.
RESULTS: Factor analysis resulted in 24 items. 21 items
with factor loadings above 0.6 were items with high clin-
ical impact scores from the clinical impact approach.
Three items with low to moderate impact scores loaded
high in the factor analysis method. 2 factors, each had
items loading from 3 similar domains, suggesting they
merged into a single factor. This led to 7 factors from an
initial 11-factor solution, similar to the clinical impact
method and with relatively minor differences in items.
CONCLUSIONS: The factor analysis approach to item
reduction produced a PTRQoL instrument with domains
similar to the clinical impact approach. Measurement
properties of the instrument developed using both
methods may decide the optimal approach. Results from
the 2 separate datasets and methods provide evidence for
the robustness of the underlying conceptual framework
of the PTRQoL.
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OBJECTIVE: To investigate one of the most common
misunderstandings on the number needed to treat (NNT)
that implies ‘certainly’, not statistically, one adverse event
can be prevented if the patients of the NNT size are
treated with the new therapy: to correct the wrong inter-
pretation, we developed the odds method for the NNT to
describe the beneﬁt vs. non-beneﬁt of therapy.
METHOD: The binomial distribution, B(n,p), was used
to model and simulate the probabilistic outcomes of
therapy with the NNT and the absolute risk reduction
(ARR) assigned to the trial size n and the event proba-
bility p, respectively. In this model, r out of n patients can
prevent the adverse event with the probability P(x = r)
deﬁned by B(n,p). We calculated the values of the P(x =
r) according to any case for r = 0, 1, 2, . . . , NNT as the
size of NNT increases from one to larger numbers. More-
over, we developed the formula, as a function of NNT, to
represent the odds of beneﬁt vs. non-beneﬁt of therapy,
i.e., P(x ≥ 1)/P(x = 0).
RESULTS: The probabilities of non-beneﬁt, i.e., P(x = 0),
were between .25 and .40 for any size of NNT. It sug-
gested the likelihood of non-beneﬁt of therapy cannot be
negligible even if the NNTs of small size seem to be ‘ben-
eﬁcial’. The numerical evaluation of the odds formula
showed that the larger the sizes of NNT became, the
smaller did the values of the odds. The progression over
the NNTs of more than ﬁve was lower than 2.0, asymp-
totically converging to e-1 (i.e., about 1.7) as the size of
NNT increases to inﬁnity.
CONCLUSIONS: Although the NNT is a quite useful
benchmark of the beneﬁt of therapy, we must interpret 
it as carefully as possible with the odds that indicates 
the ‘relative’ beneﬁt associated with the non-beneﬁt of
therapy.
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Cost minimization analysis (CMA) requires equivalent
comparators. Published guidelines have not adequately
described criteria for assuring equivalence between phar-
macotherapies.
OBJECTIVES: This study aimed to determine the pro-
portion of published CMAs that provided evidence of
equivalence between drug comparators.
METHODS: Medline, Embase, IPA, and Econlit data-
bases were searched using text words “cost” and “mini-
mization”. Inclusion criteria were: original research
claiming to be a CMA that compared costs between
drugs, and were published as full articles (i.e., not
abstracts). Data extracted included: data demonstrating
equivalence, drug class, and journal type. Adequacy of
evidence was assessed by two raters and was based on
source of evidence, quality and strength of effectiveness
data, outcome of interest, and rater’s overall impression.
Veriﬁcation was through consensus.
RESULTS: The search identiﬁed 416 studies; 358 were
rejected (272 did not compare drugs, 63 did not claim 
to be CMAs, 23 were abstracts); 12 were unavailable.
Journals publishing the 46 accepted studies were: general
medical (n = 24), hospital/pharmacy (n = 15), and health
economics (n = 2). Based on adequacy criteria, 7 (15%)
studies were judged “adequate”, 12 (26%) were “ques-
tionable”, and 27 (59%) “failed” to provide adequate
evidence of equivalence. Of those studies judged “ade-
quate”, drugs examined included: antibacterials (n = 4),
cardiovasculars (n-2), and antineoplastics (n = 1). Four of
those seven were published in general medical journals.
CONCLUSION: The majority of studies failed to provide
adequate evidence to justify using CMA as an analytic
technique. Guidelines should be developed that explicitly
specify criteria for CMA, and future authors should
comply with those guidelines. Further study should
examine CMAs not exclusively dealing with drugs and on
studies that are CMAs but do not claim to be.
